Jakob Dupont MD

Dr. Dupont is the Chief Medical Officer of Gossamer Bio. Dr. Dupont most recently served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche. He was responsible for the global development of Herceptin, Perjeta, Kadcyla, ipatesetib, taselisib, and Tecentriq, among others, and co-led the Genentech/Roche Breast Cancer Disease Area Strategy Team.

Dr. Dupont began his career in the biotech industry with Genentech/Roche where he served as Global Medical Director of Avastin and was Group Director and Medical Director overseeing the angiogenesis pipeline, playing a key role in the development and approval of Avastin in ovarian, cervical and breast cancers as well as three IND filings of novel anti-angiogenic agents. Prior to first joining Genentech/Roche in 2006, Dr. Dupont was a faculty member and laboratory researcher at Memorial Sloan-Kettering (MSK) Cancer Center and oversaw a Phase 1 solid tumor and GYN oncology clinic and a tumor immunology laboratory.

Dr. Dupont received his undergraduate degree in philosophy from Vassar College and an M.A. in philosophy from New York University. He studied pre-medical science at Columbia University and received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University. He also served as Assistant Chief Resident at MSK and completed his Medical Oncology Fellowship at MSK Cancer Center, his Internal Medicine Residency at the New-York Presbyterian Hospital—Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center in Ann Arbor.